Eplerenone Treatment for Chronic Central Serous Chorioretinopathy in Hungarian Population

Eplerenone Treatment for Chronic Central Serous Chorioretinopathy in Hungarian Population

The aim of the study is to determine the efficacy and safety of treatment with the drug eplerenone in patients with chronic central serous chorioretinopathy.

Inclusion Criteria:

• Chronic central serous chorioretinopathy (CSCR) with persistent subretinal fluid on OCT for more than 3 months after initial presentation .
• Written informed consent

Exclusion Criteria:

• Persons with impaired decision-making ability.
• Pregnant women or who are actively trying to conceive.
• Additional eye disease affecting the macula or posterior retina.
• Creatinine clearance < 50 ml/min
• Hyperkalemia > 5 mmol/l
• Serum creatinine > 2 mg/dl in men or > 1.8 mg/dl in women
• Treatment with potassium sparing agents or potassium
• Treatment with any other drugs known to cause interaction with eplerenone
• Microalbuminuria in patients with type 2 diabetes